PRIA Logo™
119-s-3677119th CongressWALLET

Dietary Supplement Listing Act of 2026

Sponsored By: Senator Durbin, Richard J. [D-IL]

Introduced

Summary

A federal dietary supplement listing and public database would require companies to submit detailed identity, label, ingredient, and marketing data for each product. The proposal ties missing or late listings to misbranding violations and blocks supplements prepared or handled with the help of debarred persons.

Personalized for You

How does this bill affect your finances?

Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Free to download

Bill Overview

Analyzed Economic Effects

2 provisions identified: 0 benefits, 1 costs, 1 mixed.

Ban on debarred-person assistance

If enacted, this would make it illegal to introduce into interstate commerce any dietary supplement that was prepared, packed, or held with help from a person debarred under the cited debarment law. Firms that use debarred contractors, suppliers, or service providers would need to stop those practices for affected products. This change would take effect upon enactment.

New supplement listing and database

If enacted, this would require the responsible person for every dietary supplement sold in the U.S. to file a federal product listing. Listings would include product identity, full ingredient lists, label text, servings, directions, warnings, allergen statements, dosage form, certain label claims, and an FDA product listing number. Foreign firms would need a U.S. agent with a domestic address and email. For products sold by January 1, 2027, listings would be due within 18 months after enactment; new products would be listed when first introduced into interstate commerce. FDA would make a public, searchable database within two years but would withhold certain business addresses and proprietary-blend amounts from public view. Failure to file required listings or updates would be treated as misbranding and could lead to FDA enforcement. Congress would be authorized to appropriate $7,872,984 for fiscal year 2026 and $6,615,000 each year for 2027–2030 to set up and staff the program; Congress must appropriate the money before it is spent.

Sponsors & CoSponsors

Sponsor

Durbin, Richard J. [D-IL]

IL • D

Cosponsors

There are no cosponsors for this bill.

Roll Call Votes

No roll call votes available for this bill.

View on Congress.gov
Back to Legislation